Autologous and allogeneic cellular therapies for high-risk pediatric solid tumors

Pediatric Clinics of North America

Volumn 57, Issue 1, 2010, Pages 47-66

  Barrett, David ^a   Fish, Jonathan D ^c   Grupp, Stephan A ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c SCHNEIDER CHILDREN'S HOSPITAL   (United States)

Author keywords

Cell based therapies; Hematopoietic stem cell transplantation; Pediatric solid tumors

Indexed keywords

(3 IODOBENZYL)GUANIDINE; (3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; ALKYLATING AGENT; ANTHRACYCLINE; BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CHIMERIC IMMUNORECEPTOR; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; PREDNISOLONE; RETINOIC ACID; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD TOXICITY; BONE MARROW DEPRESSION; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURGERY; CHILDHOOD CANCER; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; EWING SARCOMA; HIGH RISK POPULATION; HODGKIN DISEASE; HUMAN; MULTIPLE CYCLE TREATMENT; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PROGNOSIS; REVIEW; RHABDOMYOSARCOMA; SOLID TUMOR; T LYMPHOCYTE;

CHILD; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; NEOPLASMS; PATIENT SELECTION; RISK FACTORS; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 77951069140     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcl.2010.01.001     Document Type: Review

References (114)

1. Maris J.M., Hogarty M.D., Bagatell R., et al. Neuroblastoma. Lancet 2007, 369(9579):2106-2120.
2. Kletzel M., Katzenstein H.M., Haut P.R., et al. Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: results of the Chicago Pilot II Study. J Clin Oncol 2002, 20(9):2284-2292.
3. Kreissman S.G., Rackoff W., Lee M., et al. High dose cyclophosphamide with carboplatin: a tolerable regimen suitable for dose intensification in children with solid tumors. J Pediatr Hematol Oncol 1997, 19(4):309-312.
4. Aisenberg A.C. Problems in Hodgkin's disease management. Blood 1999, 93(3):761-779.
5. Dorffel W., Luders H., Ruhl U., et al. Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin's disease in children and adolescents: analysis and outlook. Klin Padiatr 2003, 215(3):139-145.
6. Schellong G., Potter R., Bramswig J., et al. High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: the German-Austrian multicenter trial DAL-HD-90. The German-Austrian Pediatric Hodgkin's Disease Study Group. J Clin Oncol 1999, 17(12):3736-3744.
7. Balwierz W., Armata J., Moryl-Bujakowska A., et al. Chemotherapy combined with involved-field radiotherapy for 177 children with Hodgkin's disease treated in 1983-1987. Acta Paediatr Jpn 1991, 33(6):703-708.
8. Schellong G., Bramswig J.H., Hornig-Franz I., et al. Hodgkin's disease in children: combined modality treatment for stages IA, IB, and IIA. Results in 356 patients of the German/Austrian Pediatric Study Group. Ann Oncol 1994, 5(Suppl 2):113-115.
9. Anselmo A.P., Meloni G., Cavalieri E., et al. Conventional salvage chemotherapy vs. high-dose therapy with autografting for recurrent or refractory Hodgkin's disease patients. Ann Hematol 2000, 79(2):79-82.
10. Ferme C., Mounier N., Divine M., et al. Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial. J Clin Oncol 2002, 20(2):467-475.
11. Yuen A.R., Horning S.J. Recent advances in the treatment of Hodgkin's disease. Curr Opin Hematol 1997, 4(4):286-290.
12. Carella A.M., Carlier P., Congiu A., et al. Autologous bone marrow transplantation as adjuvant treatment for high-risk Hodgkin's disease in first complete remission after MOPP/ABVD protocol. Bone Marrow Transplant 1991, 8(2):99-103.
13. Federico M., Bellei M., Brice P., et al. High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy. J Clin Oncol 2003, 21(12):2320-2325.
14. Linch D.C., Winfield D., Goldstone A.H., et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993, 341(8852):1051-1054.
15. Schmitz N., Pfistner B., Sextro M., et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002, 359(9323):2065-2071.
16. Williams C.D., Goldstone A.H., Pearce R., et al. Autologous bone marrow transplantation for pediatric Hodgkin's disease: a case-matched comparison with adult patients by the European Bone Marrow Transplant Group Lymphoma Registry. J Clin Oncol 1993, 11(11):2243-2249.
17. Stoneham S., Ashley S., Pinkerton C.R., et al. Outcome after autologous hemopoietic stem cell transplantation in relapsed or refractory childhood Hodgkin disease. J Pediatr Hematol Oncol 2004, 26(11):740-745.
18. Baker K.S., Gordon B.G., Gross T.G., et al. Autologous hematopoietic stem-cell transplantation for relapsed or refractory Hodgkin's disease in children and adolescents. J Clin Oncol 1999, 17(3):825-831.
19. Claviez A., Tiemann M., Luders H., et al. Impact of latent Epstein-Barr virus infection on outcome in children and adolescents with Hodgkin's lymphoma. J Clin Oncol 2005, 23(18):4048-4056.
20. Verdeguer A., Pardo N., Madero L., et al. Autologous stem cell transplantation for advanced Hodgkin's disease in children. Spanish group for BMT in children (GETMON), Spain. Bone Marrow Transplant 2000, 25(1):31-34.
21. Anderlini P., Swanston N., Rashid A., et al. Evidence of a graft-versus-Hodgkin lymphoma effect in the setting of extensive bone marrow involvement. Biol Blood Marrow Transplant 2008, 14(4):478-480.
22. Thomson K.J., Peggs K.S., Smith P., et al. Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation. Bone Marrow Transplant 2008, 41(9):765-770.
23. Anderson J.E., Litzow M.R., Appelbaum F.R., et al. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience. J Clin Oncol 1993, 11(12):2342-2350.
24. Sureda A., Robinson S., Canals C., et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008, 26(3):455-462.
25. Alvarez I., Sureda A., Caballero M.D., et al. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: results of a Spanish prospective cooperative protocol. Biol Blood Marrow Transplant 2006, 12(2):172-183.
26. Peggs K.S., Hunter A., Chopra R., et al. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 2005, 365(9475):1934-1941.
27. Cairo M.S., Gerrard M., Sposto R., et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood 2007, 109(7):2736-2743.
28. Link M.P., Shuster J.J., Donaldson S.S., et al. Treatment of children and young adults with early-stage non-Hodgkin's lymphoma. N Engl J Med 1997, 337(18):1259-1266.
29. Seidemann K., Tiemann M., Schrappe M., et al. Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood 2001, 97(12):3699-3706.
30. Kobrinsky N.L., Sposto R., Shah N.R., et al. Outcomes of treatment of children and adolescents with recurrent non-Hodgkin's lymphoma and Hodgkin's disease with dexamethasone, etoposide, cisplatin, cytarabine, and l-asparaginase, maintenance chemotherapy, and transplantation: Children's Cancer Group Study CCG-5912. J Clin Oncol 2001, 19(9):2390-2396.
31. Gross T.G., Hale G.A., He W., et al. Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents. Biol Blood Marrow Transplant 2009, [Epub ahead of print].
32. Chen A.R. High-dose therapy with stem cell rescue for pediatric solid tumors: rationale and results. Pediatr Transplant 1999, 3(Suppl 1):78-86.
33. Leavey P.J., Collier A.B. Ewing sarcoma: prognostic criteria, outcomes and future treatment. Expert Rev Anticancer Ther 2008, 8(4):617-624.
34. Leavey P.J., Mascarenhas L., Marina N., et al. Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: a report from the Children's Oncology Group. Pediatr Blood Cancer 2008, 51(3):334-338.
35. Miser J.S., Goldsby R.E., Chen Z., et al. Treatment of metastatic Ewing sarcoma/primitive neuroectodermal tumor of bone: evaluation of increasing the dose intensity of chemotherapy-a report from the Children's Oncology Group. Pediatr Blood Cancer 2007, 49(7):894-900.
36. Meyers P.A., Krailo M.D., Ladanyi M., et al. High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis. J Clin Oncol 2001, 19(11):2812-2820.
37. Burdach S., Meyer-Bahlburg A., Laws H.J., et al. High-dose therapy for patients with primary multifocal and early relapsed Ewing's tumors: results of two consecutive regimens assessing the role of total-body irradiation. J Clin Oncol 2003, 21(16):3072-3078.
38. Burdach S., van Kaick B., Laws H.J., et al. Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of the European Intergroup Study EICESS. Stem-Cell Transplant Programs at Dusseldorf University Medical Center, Germany and St. Anna Kinderspital, Vienna, Austria. Ann Oncol 2000, 11(11):1451-1462.
39. Oberlin O., Rey A., Desfachelles A.S., et al. Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Société Française des Cancers de l'Enfant. J Clin Oncol 2006, 24(24):3997-4002.
40. Bacci G., Ferrari S., Longhi A., et al. Therapy and survival after recurrence of Ewing's tumors: the Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997. Ann Oncol 2003, 14(11):1654-1659.
41. Barker L.M., Pendergrass T.W., Sanders J.E., et al. Survival after recurrence of Ewing's sarcoma family of tumors. J Clin Oncol 2005, 23(19):4354-4362.
42. Ladenstein R., Philip T., Gardner H. Autologous stem cell transplantation for solid tumors in children. Curr Opin Pediatr 1997, 9(1):55-69.
43. Crist W., Gehan E.A., Ragab A.H., et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 1995, 13(3):610-630.
44. Lager J.J., Lyden E.R., Anderson J.R., et al. Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol 2006, 24(21):3415-3422.
45. Houghton J.A., Cook R.L., Lutz P.J., et al. Melphalan: a potential new agent in the treatment of childhood rhabdomyosarcoma. Cancer Treat Rep 1985, 69(1):91-96.
46. Lazarus H.M., Herzig R.H., Graham-Pole J., et al. Intensive melphalan chemotherapy and cryopreserved autologous bone marrow transplantation for the treatment of refractory cancer. J Clin Oncol 1983, 1(6):359-367.
47. Koscielniak E., Klingebiel T.H., Peters C., et al. Do patients with metastatic and recurrent rhabdomyosarcoma benefit from high-dose therapy with hematopoietic rescue? Report of the German/Austrian Pediatric Bone Marrow Transplantation Group. Bone Marrow Transplant 1997, 19(3):227-231.
48. Pinkerton C.R., Groot-Loonen J., Barrett A., et al. Rapid VAC high dose melphalan regimen, a novel chemotherapy approach in childhood soft tissue sarcomas. Br J Cancer 1991, 64(2):381-385.
49. Bagatell R., Rumcheva P., London W.B., et al. Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy. J Clin Oncol 2005, 23(34):8819-8827.
50. Simon T., Spitz R., Faldum A., et al. New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status. J Pediatr Hematol Oncol 2004, 26(12):791-796.
51. Grupp S.A., Stern J.W., Bunin N., et al. Tandem high-dose therapy in rapid sequence for children with high-risk neuroblastoma. J Clin Oncol 2000, 18(13):2567-2575.
52. Matthay K.K., Villablanca J.G., Seeger R.C., et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999, 341(16):1165-1173.
53. Cheung N.V., Heller G. Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma. J Clin Oncol 1991, 9(6):1050-1058.
54. Berthold F., Boos J., Burdach S., et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol 2005, 6(9):649-658.
55. George R.E., Li S., Medeiros-Nancarrow C., et al. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. J Clin Oncol 2006, 24(18):2891-2896.
56. Dini G., Lanino E., Garaventa A., et al. Myeloablative therapy and unpurged autologous bone marrow transplantation for poor-prognosis neuroblastoma: report of 34 cases. J Clin Oncol 1991, 9(6):962-969.
57. Dini G., Philip T., Hartmann O., et al. Bone marrow transplantation for neuroblastoma: a review of 509 cases. EBMT Group. Bone Marrow Transplant 1989, 4(Suppl 4):42-46.
58. Kushner B.H., O'Reilly R.J., Mandell L.R., et al. Myeloablative combination chemotherapy without total body irradiation for neuroblastoma. J Clin Oncol 1991, 9(2):274-279.
59. Matthay K.K. Impact of myeloablative therapy with bone marrow transplantation in advanced neuroblastoma. Bone Marrow Transplant 1996, 18(Suppl 3):S21-S24.
60. Matthay K.K., O'Leary M.C., Ramsay N.K., et al. Role of myeloablative therapy in improved outcome for high risk neuroblastoma: review of recent Children's Cancer Group results. Eur J Cancer 1995, 31(4):572-575.
61. Pole J.G., Casper J., Elfenbein G., et al. High-dose chemoradiotherapy supported by marrow infusions for advanced neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 1991, 9(1):152-158.
62. Philip T., Ladenstein R., Lasset C., et al. 1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of European experience and conclusions. European Group for Blood and Marrow Transplant Registry Solid Tumour Working Party. Eur J Cancer 1997, 33(12):2130-2135.
63. Grupp S.A., Stern J.W., Bunin N., et al. Rapid-sequence tandem transplant for children with high-risk neuroblastoma. Med Pediatr Oncol 2000, 35(6):696-700.
64. Philip T., Ladenstein R., Zucker J.M., et al. Double megatherapy and autologous bone marrow transplantation for advanced neuroblastoma: the LMCE2 study. Br J Cancer 1993, 67(1):119-127.
65. Grupp S.A., Cohn S.L., Wall D., et al. Collection, storage, and infusion of stem cells in children with high-risk neuroblastoma: saving for a rainy day. Pediatr Blood Cancer 2006, 46(7):719-722.
66. Rill D.R., Santana V.M., Roberts W.M., et al. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 1994, 84(2):380-383.
67. Hafer R., Voigt A., Gruhn B., et al. Neuroblastoma cells can express the hematopoietic progenitor cell antigen CD34 as detected at surface protein and mRNA level. J Neuroimmunol 1999, 96(2):201-206.
68. Voigt A., Hafer R., Gruhn B., et al. Expression of CD34 and other haematopoietic antigens on neuroblastoma cells: consequences for autologous bone marrow and peripheral blood stem cell transplantation. J Neuroimmunol 1997, 78(1-2):117-126.
69. Donovan J., Temel J., Zuckerman A., et al. CD34 selection as a stem cell purging strategy for neuroblastoma: preclinical and clinical studies. Med Pediatr Oncol 2000, 35(6):677-682.
70. Kanold J., Yakouben K., Tchirkov A., et al. Long-term results of CD34(+) cell transplantation in children with neuroblastoma. Med Pediatr Oncol 2000, 35(1):1-7.
71. Reynolds C.P., Seeger R.C., Vo D.D., et al. Model system for removing neuroblastoma cells from bone marrow using monoclonal antibodies and magnetic immunobeads. Cancer Res 1986, 46(11):5882-5886.
72. Seeger R.C., Vo D.D., Ugelstad J., et al. Removal of neuroblastoma cells from bone marrow with monoclonal antibodies and magnetic immunobeads. Prog Clin Biol Res 1986, 211:285-293.
73. Wieland D.M., Swanson D.P., Brown L.E., et al. Imaging the adrenal medulla with an I-131-labeled antiadrenergic agent. J Nucl Med 1979, 20(2):155-158.
74. Geatti O., Shapiro B., Sisson J.C., et al. Iodine-131 metaiodobenzylguanidine scintigraphy for the location of neuroblastoma: preliminary experience in ten cases. J Nucl Med 1985, 26(7):736-742.
75. Tepmongkol S., Heyman S. 131I MIBG therapy in neuroblastoma: mechanisms, rationale, and current status. Med Pediatr Oncol 1999, 32(6):427-431. [discussion: 432].
76. Matthay K.K., DeSantes K., Hasegawa B., et al. Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J Clin Oncol 1998, 16(1):229-236.
77. DuBois S.G., Messina J., Maris J.M., et al. Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma. J Clin Oncol 2004, 22(12):2452-2460.
78. Goldberg S.S., DeSantes K., Huberty J.P., et al. Engraftment after myeloablative doses of 131I-metaiodobenzylguanidine followed by autologous bone marrow transplantation for treatment of refractory neuroblastoma. Med Pediatr Oncol 1998, 30(6):339-346.
79. Corbett R., Pinkerton R., Tait D., et al. [131I]metaiodobenzylguanidine and high-dose chemotherapy with bone marrow rescue in advanced neuroblastoma. J Nucl Biol Med 1991, 35(4):228-231.
80. Gaze M.N., Wheldon T.E., O'Donoghue J.A., et al. Multi-modality megatherapy with [131I]meta-iodobenzylguanidine, high dose melphalan and total body irradiation with bone marrow rescue: feasibility study of a new strategy for advanced neuroblastoma. Eur J Cancer 1995, 31(2):252-256.
81. Klingebiel T., Bader P., Bares R., et al. Treatment of neuroblastoma stage 4 with 131I-meta-iodo-benzylguanidine, high-dose chemotherapy and immunotherapy. A pilot study. Eur J Cancer 1998, 34(9):1398-1402.
82. Matthay K.K., Tan J.C., Villablanca J.G., et al. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a New Approaches to Neuroblastoma Therapy Consortium Study. J Clin Oncol 2006, 24(3):500-506.
83. Graham-Pole J. The role of marrow autografting in neuroblastoma. Bone Marrow Transplant 1989, 4(1):3.
84. Matthay K.K., Seeger R.C., Reynolds C.P., et al. Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma: a report from the Children's Cancer Group. J Clin Oncol 1994, 12(11):2382-2389.
85. Childs R.W., Clave E., Tisdale J., et al. Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: evidence for a graft-versus-tumor effect. J Clin Oncol 1999, 17(7):2044-2049.
86. Bay J.O., Fleury J., Choufi B., et al. Allogeneic hematopoietic stem cell transplantation in ovarian carcinoma: results of five patients. Bone Marrow Transplant 2002, 30(2):95-102.
87. Uhlin M., Okas M., Karlsson H., et al. Increased frequency and responsiveness of PSA-specific T cells after allogeneic hematopoetic stem-cell transplantation. Transplantation 2009, 87(4):467-472.
88. Zetterquist H., Hentschke P., Thorne A., et al. A graft-versus-colonic cancer effect of allogeneic stem cell transplantation. Bone Marrow Transplant 2001, 28(12):1161-1166.
89. Ringden O., Karlsson H., Olsson R., et al. The allogeneic graft-versus-cancer effect. Br J Haematol 2009, 147(5):614-633.
90. Kamiryo Y., Eto M., Yamada H., et al. Donor CD4 T cells are critical in allogeneic stem cell transplantation against murine solid tumor. Cancer Res 2009, 69(12):5151-5158.
91. Gac A.C., Chantepie S., Leporrier M., et al. Full response of a localized renal tumour after reduced-intensity conditioned hematopoietic stem cell transplantation. Case Report Med 2009, 2009:879765.
92. Inoue M., Nakano T., Yoneda A., et al. Graft-versus-tumor effect in a patient with advanced neuroblastoma who received HLA haplo-identical bone marrow transplantation. Bone Marrow Transplant 2003, 32(1):103-106.
93. Srinivasan R., Barrett J., Childs R. Allogeneic stem cell transplantation as immunotherapy for nonhematological cancers. Semin Oncol 2004, 31(1):47-55.
94. Ladenstein R., Lasset C., Hartmann O., et al. Comparison of auto versus allografting as consolidation of primary treatments in advanced neuroblastoma over one year of age at diagnosis: report from the European Group for Bone Marrow Transplantation. Bone Marrow Transplant 1994, 14(1):37-46.
95. Cheung N.K., Kushner B.H., Kramer K. Monoclonal antibody-based therapy of neuroblastoma. Hematol Oncol Clin North Am 2001, 15(5):853-866.
96. Simon T., Hero B., Faldum A., et al. Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma. J Clin Oncol 2004, 22(17):3549-3557.
97. Powell J.L., Bunin N.J., Callahan C., et al. An unexpectedly high incidence of Epstein-Barr virus lymphoproliferative disease after CD34+ selected autologous peripheral blood stem cell transplant in neuroblastoma. Bone Marrow Transplant 2004, 33(6):651-657.
98. Mackall C.L., Fleisher T.A., Brown M.R., et al. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 1994, 84:2221-2228.
99. Mackall C.L., Stein D., Fleisher T.A., et al. Prolonged CD4 depletion after sequential autologous peripheral blood progenitor cell infusions in children and young adults. Blood 2000, 96:754-762.
100. June C.H. Adoptive T cell therapy for cancer in the clinic. J Clin Invest 2007, 117(6):1466-1476.
101. June C.H. Principles of adoptive T cell cancer therapy. J Clin Invest 2007, 117(5):1204-1212.
102. Levine B.L., Ueda Y., Craighead N., et al. CD28 ligands CD80 (B7-1) and CD86 (B&-2) induce long-term autocrine growth of CD4+ T cells and induce similar patterns of cytokine secretion in vitro. Int Immunol 1995, 7:891-904.
103. Levine B.L., Bernstein W., Craighead N., et al. Ex vivo replicative potential of adult human peripheral blood CD4+ T cells. Transplant Proc 1997, 29:2028.
104. Levine B.L., Cotte J., Small C.C., et al. Large-scale production of CD4+ T cells from HIV-1-infected donors after CD3/CD28 costimulation. J Hematother 1998, 7:437-448.
105. Laport G.G., Levine B.L., Stadtmauer E.A., et al. Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation. Blood 2003, 102:2004-2013.
106. Rapoport A.P., Stadtmauer E.A., Aqui N., et al. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med 2005, 11(11):1230-1237.
107. Islam A., Kageyama H., Takada N., et al. High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 2000, 19(5):617-623.
108. Azuhata T., Scott D., Takamizawa S., et al. The inhibitor of apoptosis protein survivin is associated with high-risk behavior of neuroblastoma. J Pediatr Surg 2001, 36(12):1785-1791.
109. Coughlin C.M., Fleming M.D., Carroll R.G., et al. Immunosurveillance and survivin-specific T-cell immunity in children with high-risk neuroblastoma. J Clin Oncol 2006, 24(36):5725-5734.
110. Eshhar Z., Waks T., Gross G., et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A 1993, 90(2):720-724.
111. Rossig C., Bollard C.M., Nuchtern J.G., et al. Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes. Int J Cancer 2001, 94(2):228-236.
112. Park J.R., Digiusto D.L., Slovak M., et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther 2007, 15(4):825-833.
113. Pule M.A., Savoldo B., Myers G.D., et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008, 14(11):1264-1270.
114. Trahair T.N., Vowels M.R., Johnston K., et al. Long-term outcomes in children with high-risk neuroblastoma treated with autologous stem cell transplantation. Bone Marrow Transplant 2007, 40(8):741-746.